Hori­zon adds 'se­vere hear­ing im­pair­men­t' warn­ing to block­buster's la­bel

The FDA re­cent­ly added a new warn­ing and pre­cau­tion to the la­bel of Hori­zon’s block­buster mon­o­clon­al an­ti­body Te­pez­za (tepro­tu­mum­ab-trbw), which is used as a treat­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER